Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas
Description: PROJECT NARRATIVE: CAR based immunotherapies are now credentialed as potent tools against hematologic malignancies and early signals suggest that these therapeutics may prove beneficial against brain tumors. Building upon impressive results in preclinical models, this project will undertake a Phase I trial of GD2-CAR T cells in H3K27M diffuse midline gliomas, universally lethal tumors of childhood and young adults. The project seeks to ensure the safety of this therapy for patients with brainstem gliomas where the risk of toxicity due to tumor edema is high, will use novel approaches to measure clinical efficacy and seek to define biomarkers or response, and will undertake studies focused on interrogating the biology of myeloid cell activation following CNS directed CAR T cell therapies that has been observed both in preclinical and clinical studies.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2021-08-06
End date: 2026-07-31
Investigator: CRYSTAL MACKALL
Institution: STANFORD UNIVERSITY
Funded outputs count: 21
Funder award ID: R01CA263500
OpenAlex ID: G9000893402